FDA neuroscience chief Billy Dunn, who led Aduhelm approval, will leave agency
The FDA’s top neuroscience expert Billy Dunn, who was embroiled in controversy over his close ties with industry ahead of two key Alzheimer’s drug approvals, has decided to leave the agency effective immediately, according to an internal email obtained by Endpoints News.
“Billy has decided to retire from the FDA and explore other opportunities while continuing his focus on improving the lives of patients with neurological diseases,” Peter Stein, head of the Office of New Drugs, said in the email.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.